# EQ — Equillium Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** EQ  
**Sources:** 14  
**Published:** 2026-10-26  
**Canonical:** https://app.k3vl4r.com/research/deep-research-eq-equillium-inc-catalysts-narrative-risks-9348

---

## Equillium Inc. (Nasdaq: EQ) — Research Snapshot as of Oct 26, 2026

Equillium is a clinical-stage biotechnology company (La Jolla, CA) developing therapies for autoimmune and inflammatory disorders, currently focused on its lead candidate **EQ504** (an oral, colon-targeted aryl hydrocarbon receptor [AhR] modulator for ulcerative colitis, plus an inhaled formulation for lung disease) and **EQ302** (an oral bispecific IL-15/IL-21 inhibitor for celiac disease) [[1]](https://finance.yahoo.com/healthcare/articles/equillium-receives-australian-regulatory-clearance-200500514.html), [[4]](https://finance.yahoo.com/healthcare/articles/equillium-reports-second-quarter-2026-200500246.html), [[7]](https://www.equilliumbio.com/investors/press-releases/news-details/2026/Equillium-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Corporate-Highlights/default.aspx), [[15]](https://stockanalysis.com/stocks/eq/). The stock last closed at ~$1.23 on Oct 23, 2026, with a market cap of ~$78M and no revenue [[9]](https://tickernerd.com/stock/eq-forecast/), [[11]](https://stockanalysis.com/stocks/eq/forecast/), [[13]](https://www.marketbeat.com/stocks/NASDAQ/EQ/).

---

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-eq-equillium-inc-catalysts-narrative-risks-9348 (free to sign up)._
